Trial · NCT00689390
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Relapse During the LTFU Among Sustained Responders From Previous Treatment Studies With Boceprevir or Narlaprevir (Durability of Virologic Response) | Previous SVR on Boceprevir + PR | 8 | participants | ||
| Number of Participants With Relapse During the LTFU Among Sustained Responders From Previous Treatment Studies With Boceprevir or Narlaprevir (Durability of Virologic Response) | Previous SVR on Narlaprevir + PR | 0 | participants | ||
| Number of Participants With Relapse During the LTFU Among Sustained Responders From Previous Treatment Studies With Boceprevir or Narlaprevir (Durability of Virologic Response) | Previous SVR on PR Only | 1 | participants | ||
| Kaplan-Meier Exposure-adjusted Relapse Rate | Previous SVR on Boceprevir + PR | 2.3 | relapses per 1,000 person-years | ||
| Kaplan-Meier Exposure-adjusted Relapse Rate | Previous SVR on Narlaprevir + PR | 0 | relapses per 1,000 person-years | ||
| Kaplan-Meier Exposure-adjusted Relapse Rate | Previous SVR on PR Only | 2.2 | relapses per 1,000 person-years | ||
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | V36A TE-RAVs detected | 6 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | __V36A TE-RAVs returned to WT (out of 6) | 6 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | V36G TE-RAVs detected | 1 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | __V36G TE-RAVs returned to WT (out of 1) | 1 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | V36L TE-RAVs detected | 9 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | __V36L TE-RAVs returned to WT (out of 9) | 8 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | V36M TE-RAVs detected | 142 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | __V36M TE-RAVs returned to WT (out of 142) | 135 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | F43C TE-RAVs detected | 3 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | __F43C TE-RAVs returned to WT (out of 3) | 3 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | T54A TE-RAVs detected | 40 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | __T54A TE-RAVs returned to WT (out of 40) | 40 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | T54C TE-RAVs detected | 2 | participants | |
| Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci | Participants From Boceprevir Studies With TE-RAVs | __T54C TE-RAVs returned to WT (out of 2) | 2 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00689390/results